Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model

Lignende værker

• Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC
  af: Tosch, Caroline, et al.
  Udgivet: (2017)
• Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition
  af: Kleinpeter, Patricia, et al.
  Udgivet: (2016)
• By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1
  af: Kleinpeter, Patricia, et al.
  Udgivet: (2019)
• Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
  af: Bendjama, Kaïdre, et al.
  Udgivet: (2017)
• Intravenous injection of a modified vaccinia ankara virus induces intratumoral CD8+ lymphocyte infiltration favoring tumor control in an orthotopic tumor model upon combinatorial treatment with a TLR9 agonist
  af: Fend, Laetitia, et al.
  Udgivet: (2014)